Future treatments for Parkinson's disease: surfing the PD pipeline.
Our current wish list for the treatment of Parkinson's disease (PD) includes therapies that will provide robust and sustained antiparkinsonian benefit through the day, ameliorate or prevent dyskinesia, and slow or prevent the progression of the disease. In this article, I review selected new therapies in clinical development for motor features or treatment complications of PD, and some that may slow disease progression. These include adenosine 2a (A2a) antagonists (istradefylline, preladenant, and SYN115), levodopa/carbidopa intestinal gel (LCIG), IPX066--an extended-release formulation of carbidopa/levodopa, XP21279--a sustained-release levodopa prodrug, ND0611--a carbidopa subcutaneous patch, safinamide--a mixed mechanism of action medication that may provide both MAO-B and glutamate inhibition, PMY50028--an oral neurotrophic factor inducer, antidyskinesia medications (AFQ056 and fipamezole), and gene therapies (AAV2-neurturin and glutamic acid decarboxylase gene transfer). Some of these therapies will never be proven efficacious and will not come to market while others may play a key role in the future treatment of PD.
Department of Neurology, College of Medicine, University of South Florida, Tampa, Florida 33606, USA. rhauser@health.usf.edu
Robert A
RA
Hauser
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018014:Gene Transfer Techniques / Q000639:trends; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009480:Neuropharmacology / Q000379:methods* / Q000639:trends*; D010300:Parkinson Disease / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*
D000978:Antiparkinson Agents; D007980:Levodopa